SWISS pharmaceuticals giant Novartis has announced that its net profit fell 1.0 per cent in 2013 to $US9.2 billion ($A10.51 billion), blaming the impact of unfavourable exchange rates.
Without taking into account rate fluctuations - notably the fall of the Japanese yen and emerging markets' currencies against the dollar - the group said that profit rose by 7.0 per cent last year.
"Novartis delivered strong performance in 2013, growing both net sales and core operating income in constant currencies while absorbing patent expirations," chief executive Joseph Jimenez said in a statement.
"We maintained good momentum in innovation," he underlined, noting that 18 new Novartis drugs had won approval from regulators and that the US Federal Drug Administration had granted three products "breakthrough therapy" status.
"Our growth products continued to expand, rejuvenating our portfolio and reinforcing our growth prospects," Jimenez said.
Operation profit fell by 3.0 per cent to $US10.9 billion, while sales climbed 2.0 per cent to $US57.9 billion.
Like other pharmaceuticals firms, Novartis faces a strong challenges from makers of generic drugs, sales of which knocked $US2.2 billion off the Swiss group's figures last year.
The Novartis board is to propose a dividend of 2.45 Swiss francs ($A3.12) per share, down from 2.30 francs last year.
Anda sedang membaca artikel tentang
Pharma giant Novartis reports profits dip
Dengan url
https://lagisuntuks.blogspot.com/2014/01/pharma-giant-novartis-reports-profits.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Pharma giant Novartis reports profits dip
namun jangan lupa untuk meletakkan link
Pharma giant Novartis reports profits dip
sebagai sumbernya
0 komentar:
Posting Komentar